Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device

Study Overview
=================
Brief Summary
-----------------
Ceftobiprole is a very active new cephalosporin on staphylococci resistant to methicillin (SEMR: Staphylococcus epidermidis Resistant to Meticillin, SAMR: Staphylococcus aureus Resistant to Meticillin) and / or vancomycin; it is also very active on pneumococci resistant to penicillin and / or 3rd generation cephalosporins. This new drug has AMM in nosocomial respiratory infections, Animal work shows the efficacy of ceftobiprole in gram negative bacillus meningeal infections. The rationale of this study is based on the antibacterial spectrum of ceftobiprole, which would therefore be useful in the treatment of staphylococcal bacterial meningitis resistant patients (SEMR or SAMR) encountered in intensive care and / or neurosurgery and in the treatment of pneumococcal meningitis. To validate these possibilities, it is necessary to know the concentrations of ceftobiprole in the meningeal space.

Official Title
-----------------
Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device

Conditions
-----------------
Inflamed Meninges, Suspected Meningitis, Ventriculitis

Intervention / Treatment
-----------------
* Drug: Ceftobiprole Medocaril
* Other: Blood samples and cerebrospinal fluid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (> 18 years) Provision of informed consent prior to any study specific procedures Female patients of childbearing potential may be entered if pregnancy testing is negative and the patient agrees to abstain from procreational sexual intercourse or must use double-barrier contraceptive measures for the duration of the study Presence of an indwelling external CSF access device (ventriculostomy or lumbar drain) Presence of inflamed meninges as a result of documented or suspected meningitis or ventriculitis. Patients with both clinical symptoms (fever, headache, meningismus, and altered mentation) and laboratory parameters (CSF leukocytosis, defined as a CSF white blood cell count [WBC] of >103, elevated CSF protein, defined as CSF protein of >1g/l, reduced CSF glucose, defined as CSF glucose of <0.3g/l, or a positive CSF Gram stain or culture) indicative of CNS infection were deemed to have definitive bacterial meningitis/ventriculitis. Inflamed meninges were defined as the presence of >5 leukocytes/mm3 of CSF. Person with antibacterial treatment (including treatment for the current meningitis or ventriculitis) Glycemia above 3 mmol/l and below 10 mmol/l Natremia below 145 mmol/l Capnia below 45 mmHg No other patient included within 72 hours from D0 (treatment period) of the previous patient Agreement of the scientific committee Exclusion Criteria: Hypersensitivity to MABELIO® (ceftobiprole) or to one of its excipient or another 3rd cephalosporin Hypersensitivity to cephalosporin Immediate and severe hypersensitivity to β-lactam antimicrobial other than Mabelio and other cephalosporins Pregnant or breast feeding women Renal insufficiency defined as creatinine clearance < 50 mL/min Patient with creatinine clearance > 150 mL/min Patients with conditions known or suspected to alter pharmacokinetics (i.e., burn or cystic fibrosis patients) Refusal to participate Person not affiliated to the social security Absolute necessity of immediate removing the device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0|
|Other: Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of concentration of ceftobiprole in blood |  | Before and immediately the end of the perfusion and then at 0.5, 1, 3, 6, 12 and 24 hours | 
| Measurement of concentration of ceftobiprole in cerebrospinal fluid |  | Before and immediately the end of the perfusion and then at 0.5, 1, 3, 6, 12 and 24 hours |